- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Journal of clinical immunology. - 40, 8 (2020) , 1207-1210, ISSN: 1573-2592
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2020
- Creator
-
Wegehaupt, Oliver Philipp
Muckenhaupt, Tina
Johnson, Matthew B.
Schwab, Karl Otfried
Speckmann, Carsten
- DOI
-
10.1007/s10875-020-00864-w
- URN
-
urn:nbn:de:bsz:25-freidok-1678281
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wegehaupt, Oliver Philipp
- Muckenhaupt, Tina
- Johnson, Matthew B.
- Schwab, Karl Otfried
- Speckmann, Carsten
- Universität
Time of origin
- 2020
Other Objects (12)
Inhibition of the JAK2-STAT3 pathway using ruxolitinib as a therapeutic option for pulmonary hypertension
miRNA-7145-cuedc2 axis controls hematopoiesis through JAK1/STAT3 signaling pathway
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
The long noncoding RNA H19 controls endothelial cell functions by STAT3 repression
Targeting STAT3 Signaling in COL1+ Fibroblasts Controls Colitis-Associated Cancer in Mice
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V
Ruxolitinib (Addendum zum Auftrag A15-13)
Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Inhibition of the JAK2-STAT3 pathway using ruxolitinib as a therapeutic option for pulmonary hypertension
miRNA-7145-cuedc2 axis controls hematopoiesis through JAK1/STAT3 signaling pathway
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
The long noncoding RNA H19 controls endothelial cell functions by STAT3 repression
Targeting STAT3 Signaling in COL1+ Fibroblasts Controls Colitis-Associated Cancer in Mice
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V
Ruxolitinib (Addendum zum Auftrag A15-13)
Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Inhibition of the JAK2-STAT3 pathway using ruxolitinib as a therapeutic option for pulmonary hypertension
miRNA-7145-cuedc2 axis controls hematopoiesis through JAK1/STAT3 signaling pathway
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
The long noncoding RNA H19 controls endothelial cell functions by STAT3 repression
Targeting STAT3 Signaling in COL1+ Fibroblasts Controls Colitis-Associated Cancer in Mice
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V
Ruxolitinib (Addendum zum Auftrag A15-13)
Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies